PICO Portalanswers from OpenAlex & ORCID
David P. Carbone
ResearcherPublications, citations & collaboration network
David P. Carbone is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does David P. Carbone have?
PICO Portalindexed works
David P. Carbone has 969 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David P. Carbone have?
PICO Portalcitation count
David P. Carbone has 46,420 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of David P. Carbone?
PICO Portalh-index
David P. Carbone has an h-index of 98 in OpenAlex.
What is the i10-index of David P. Carbone?
PICO Portali10-index
David P. Carbone has an i10-index of 350 in OpenAlex.
What is the ORCID of David P. Carbone?
PICO Portalorcid
The ORCID for David P. Carbone is on the source record.
What is the OpenAlex record for David P. Carbone?
PICO Portalopenalex
The OpenAlex for David P. Carbone is on the source record.
What are the most-cited papers on David P. Carbone?
PICO Portalmost cited works
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer
Non-small-cell lung cancer
Cesare Gridelli, Antônio Rossi, David P. Carbone, Juliana Guarize, Niki Karachaliou, Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
Dmitry I. Gabrilovich, Tadao Ishida, Tsunehiro Oyama, Sophia Ran, Vladimir Kravtsov, Sorena Nadaf, David P. Carbone